Vera-Izaguirre DS, Karam-Orantes M, Vega-Memije E

Idioma: Español
Referencias bibliográficas: 29
Paginas: 27-32
Archivo PDF: 106.65 Kb.

RESUMEN

Antecedentes: El penfigoide ampolloso (PA) es una enfermedad autoinmune frecuentemente observada en pacientes de edad avanzada. Su diagnóstico se establece con la combinación de características clínicas, histológicas e inmunopatológicas. El PA se caracteriza por la presencia de ampollas tensas asentadas en piel normal o eritematosa que tienen predilección por las extremidades y frecuentemente la enfermedad tiende a generalizarse. En el estudio histológico se observa una ampolla subepidérmica, con predominio de eosinófilos. Los estudios de inmunofluorescencia (IF) directa de piel perilesional muestran depósitos lineales de IgG y/o C3 en la zona de la membrana basal (ZMB). Pueden utilizarse corticosteroides tópicos para el penfigoide localizado; para el generalizado se utilizan dosis altas de corticosteroides y otras drogas inmunosupresoras, como dapsone y azatioprina. El PA es una enfermedad autolimitada, pero su curso y pronóstico va a depender del estado general del paciente geriátrico.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Mutasim DF. Autoimmune bullous dermatoses in the elderly. diagnosis and management. Drugs Aging 2003; 20: 664-78.

2. Colbert RL, Allen DM, Eastwood D, Fairley JA. Mortality rate of bullous pemphigoid in a US Medical Center. J Invest Dermatol 2004; 122: 1091-95.

3. Khumalo NP, Wojnarowska F et al. A systematic review of treatments for bullous pemphigoid. Br J Dermatol 2002; 138: 385-89.

4. Khumalo NP. Management of bullous pemphigoid. recommendations for immunomodulatory treatments. Am J Clin Dermatol 2004; 5: 319-26.

5. 5 Fitzpatrick’s et al. Dermatology in General Medicine. McGraw-Hill Sixth Edition; Volume I: 574-79.

6. Bologna JL, Jean L, Jorrizzo JL, Joseph L, Rapini RP. Dermatology Mosby 2003: 463-470.

7. Sison-Fonacier L, Bystryn JC. Regional variations in antigenic properties of skin: a possible cause for disease-specific distribution of skin lesion. J Exp Med 1986; 164: 2125-30.

8. Barnhill RL, Crouson AN. Textbook of dermatopathology. McGraw- Hill Second edition. 1998: 181-83.

9. Mariotti FG, Terracina M, Ruffelli M., Cordiali-Fei P, Sera F, Zambruno G, Mastrogiacomo A, Di Zenzo G. Development of a novel ELISA system for detection of anti-BP 180 IgG and characterization of autoantibody profile in bullous pemphigoid patients. British Journal of Dermatology 2004; 151: 1004-10.

10. Diaz LA et al. Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestations sera. Immunolocalization of this protein to the hemidesmosome. J Clin Invest 1990; 86: 1088-94.

11. Diya F, Mutasim M. Management of autoinmmune bullous diseases: Pharmacology and therapeutics. J Am Acad Dermatol 2004; 51: 859-877.

12. Roijeau JP, Benichou J et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002; 346: 321-27.

13. Wojnarowska F, Kirtschig G, Highet AS et al. Guidelines for the management of bullous pemphigoid. Br J Dermatol 2002; 147: 214-21.

14. Eaglitein WH, Siegel J. High-dose methylprednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1984; 120: 1157-65.

15. Fine JD. Management of acquired bullous skin disease. New Engl J Med 1995; 333: 1475.

16. Ahmed AR. Azathioprine. Int J Dermatol 1981; 20: 461-69.

17. Ahmed AR. Cyclophosphamide review of relevant pharmacology and clinical use. J Am Acad Dermatol 1984; 6: 1115-1126.

18. Thiovolet J, Bartelemy H, Rigot-Muller G et al. Effects of cyclosporine on bullous pemphigoid and pemphigus. Lancet 1985; I: 334-335.

19. Person JR. Bullous pemphigoid responding to sulfapyridine and the sulfones. Arch Dermatol 1997; 113: 610-615.

20. Venning VA et al. Dapsone as first line therapy for bullous pemphigoid. Br J Dermatol 1989; 120: 83-87.

21. Bouscarat F et al. Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases. J Am Acad Dermatol 1996; 34: 686.

22. Jeffes EW, Ahmed AR. Adjuvant therapy of bullous pemphigoid with dapsone. Clin Exp Dermatol 1991; 25: 691-697.

23. Goldberg NS, Roenigk Jr HH et al. Plasmapheresis therapy for bullous pemphigoid. Arch Dermatol 1985; 121: 1484-85. 24. Roujeau JC, Guillaune JC, Morel P et al. Plasma ex change in bullous pemphigoid. Lancet 1984; II: 486-89.

24. Enginneer L, Ahmed AR. Role of intravenous immunoglobulin in the treatment of bullous pemphigoid: analysis of current data. J Am Acad Dermatol 2001; 44: 83-88.

25. Ahmed AR. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001; 45: 825-35.

26. Thomas I, Khorenian S, Arbesteld DM. Treatment of generalized bullous pemphigoid with oral tetracycline. J Am Acad Dermatol 1993; 28: 74-77.

27. Milligan A, Hutchinson P. The use of chlorambucil in the treatment of bullous pemphigoid. J Am Acad Dermatol 1990; 22: 769-01.

28. Chu J, Bradley M, Marinkovich MP. Topical tacrolimus is a useful adjunctive therapy for bullous pemphigoid. Arch Dermatol 2003; 139: 813-15.

29. Rzany B, Partscht K, Jung M et al. Risk factors for lethal outcome in patients with bullous pemphigoid. N Engl J Med 2002; 346: 321-27.